218 related articles for article (PubMed ID: 26668132)
1. The immunogenicity of platelet-derived FVIII in hemophilia A mice with or without preexisting anti-FVIII immunity.
Chen Y; Schroeder JA; Chen J; Luo X; Baumgartner CK; Montgomery RR; Hu J; Shi Q
Blood; 2016 Mar; 127(10):1346-54. PubMed ID: 26668132
[TBL] [Abstract][Full Text] [Related]
2. The impact of GPIbα on platelet-targeted FVIII gene therapy in hemophilia A mice with pre-existing anti-FVIII immunity.
Chen J; Schroeder JA; Luo X; Montgomery RR; Shi Q
J Thromb Haemost; 2019 Mar; 17(3):449-459. PubMed ID: 30609275
[TBL] [Abstract][Full Text] [Related]
3. Platelet VIII pack evades immune detection.
Ragni MV
Blood; 2016 Mar; 127(10):1222-4. PubMed ID: 26965921
[TBL] [Abstract][Full Text] [Related]
4. The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies.
Shi Q; Schroeder JA; Kuether EL; Montgomery RR
J Thromb Haemost; 2015 Jul; 13(7):1301-9. PubMed ID: 25955153
[TBL] [Abstract][Full Text] [Related]
5. Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity.
Shi Q; Fahs SA; Wilcox DA; Kuether EL; Morateck PA; Mareno N; Weiler H; Montgomery RR
Blood; 2008 Oct; 112(7):2713-21. PubMed ID: 18495954
[TBL] [Abstract][Full Text] [Related]
6. Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated.
Chen Y; Luo X; Schroeder JA; Chen J; Baumgartner CK; Hu J; Shi Q
J Thromb Haemost; 2017 Oct; 15(10):1994-2004. PubMed ID: 28799202
[TBL] [Abstract][Full Text] [Related]
7. Pre-existing anti-factor VIII immunity alters therapeutic platelet-targeted factor VIII engraftment following busulfan conditioning through cytotoxic CD8 T cells.
Jing W; Baumgartner CK; Xue F; Schroeder JA; Shi Q
J Thromb Haemost; 2023 Mar; 21(3):488-498. PubMed ID: 36696197
[TBL] [Abstract][Full Text] [Related]
8. Comparison of platelet-derived and plasma factor VIII efficacy using a novel native whole blood thrombin generation assay.
Baumgartner CK; Zhang G; Kuether EL; Weiler H; Shi Q; Montgomery RR
J Thromb Haemost; 2015 Dec; 13(12):2210-9. PubMed ID: 26453193
[TBL] [Abstract][Full Text] [Related]
9. Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity.
Kuether EL; Schroeder JA; Fahs SA; Cooley BC; Chen Y; Montgomery RR; Wilcox DA; Shi Q
J Thromb Haemost; 2012 Aug; 10(8):1570-80. PubMed ID: 22632092
[TBL] [Abstract][Full Text] [Related]
10. Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A.
Shi Q; Wilcox DA; Fahs SA; Fang J; Johnson BD; DU LM; Desai D; Montgomery RR
J Thromb Haemost; 2007 Feb; 5(2):352-61. PubMed ID: 17269937
[TBL] [Abstract][Full Text] [Related]
11. Platelet-Targeted FVIII Gene Therapy Restores Hemostasis and Induces Immune Tolerance for Hemophilia A.
Cai Y; Shi Q
Front Immunol; 2020; 11():964. PubMed ID: 32595633
[TBL] [Abstract][Full Text] [Related]
12. In vivo enrichment of genetically manipulated platelets corrects the murine hemophilic phenotype and induces immune tolerance even using a low multiplicity of infection.
Schroeder JA; Chen Y; Fang J; Wilcox DA; Shi Q
J Thromb Haemost; 2014 Aug; 12(8):1283-93. PubMed ID: 24931217
[TBL] [Abstract][Full Text] [Related]
13. Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies.
Shi Q; Wilcox DA; Fahs SA; Weiler H; Wells CW; Cooley BC; Desai D; Morateck PA; Gorski J; Montgomery RR
J Clin Invest; 2006 Jul; 116(7):1974-82. PubMed ID: 16823491
[TBL] [Abstract][Full Text] [Related]
14. Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A mice.
Wroblewska A; van Haren SD; Herczenik E; Kaijen P; Ruminska A; Jin SY; Zheng XL; van den Biggelaar M; ten Brinke A; Meijer AB; Voorberg J
Blood; 2012 May; 119(22):5294-300. PubMed ID: 22498747
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of the Thrombus Formation in Transgenic Mice with Platelet-Targeted Factor VIII Expression.
Wang Y; Mao J; Li L; Xiao B; Ruan Z; Liu Y; Zhang G; Wang D; Mi JQ; Fang C; Xi X; Shi X; Wang J
Thromb Haemost; 2022 May; 122(5):755-766. PubMed ID: 34587639
[TBL] [Abstract][Full Text] [Related]
16. B cell-activating factor modulates the factor VIII immune response in hemophilia A.
Doshi BS; Rana J; Castaman G; Shaheen MA; Kaczmarek R; Butterfield JS; Meeks SL; Leissinger C; Biswas M; Arruda VR
J Clin Invest; 2021 Apr; 131(8):. PubMed ID: 33651716
[TBL] [Abstract][Full Text] [Related]
17. A Retrospective Study of the Cytokine Profile Changes in Mice with FVIII Inhibitor Development After Adeno-Associated Virus-Mediated Gene Therapy in a Hemophilia A Mouse Model.
Sun J; Yuan Z; Abajas YL; Szollosi DE; Hu G; Hua B; Xiao X; Li C
Hum Gene Ther; 2018 Mar; 29(3):381-389. PubMed ID: 28922951
[TBL] [Abstract][Full Text] [Related]
18. Ectopic Expression of FVIII in HPCs and MSCs Derived from hiPSCs with Site-Specific Integration of
Zhao J; Zhou M; Wang Z; Wu L; Hu Z; Liang D
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054807
[TBL] [Abstract][Full Text] [Related]
19. Concurrent influenza vaccination reduces anti-FVIII antibody responses in murine hemophilia A.
Lai JD; Moorehead PC; Sponagle K; Steinitz KN; Reipert BM; Hough C; Lillicrap D
Blood; 2016 Jun; 127(26):3439-49. PubMed ID: 27034428
[TBL] [Abstract][Full Text] [Related]
20. Von Willebrand factor-specific antibodies developing upon treatment of FVIII-deficient mice with different FVIII preparations.
Kallas A; Kuuse S; Maimets T; Pooga M
Acta Haematol; 2008; 119(4):244-7. PubMed ID: 18594135
[No Abstract] [Full Text] [Related]
[Next] [New Search]
